Podcast
If 400m+ people live with COPD, why aren’t we talking about it?
In the second Behind the Science episode, Dr. Kat Arney speaks with Professor Dave Singh, a specialist in respiratory pharmacology at the University of Manchester, and Dr. Kaivan Khavandi, SVP and Global Head of Respiratory, Immunology and Inflammation Research at GSK, to take a closer look at a disease that affects a fundamental part of life – breathing. Together they explore COPD, unpacking how it affects everyday life and why severe exacerbations, or attacks, can have such serious consequences.
Who we are
As a focused biopharma company, we discover, develop and deliver medicines and vaccines to create value for patients and shareholders. We aim to positively impact the health of 2.5 billion people by the end of the decade.Our R&D focus is on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.
Behind the Science
